COSHH Risk Assessment for Research Peptides UK: 2026 Laboratory Compliance Guide | Daxer Labs

Under the Control of Substances Hazardous to Health (COSHH) Regulations 2002, UK employers and research institutions have a legal duty to assess the risks of any hazardous substance used in the workplace — and that includes research peptides. As more university departments, contract research organisations and private laboratories order peptides for in-vitro and preclinical work, a properly documented COSHH risk assessment for research peptides UK labs can rely on is becoming a standard part of onboarding a new compound, not an afterthought. This guide sets out what a COSHH assessment for peptide handling should cover, the hazards specific to lyophilised powders and reconstituted solutions, and the documentation researchers should keep on file.

Note: This article is written for laboratory health-and-safety and research-compliance purposes. Daxer Labs supplies all peptides strictly for research use, not for human or animal use, and this guide does not constitute formal health-and-safety advice — always consult your institution's health and safety officer.

What Is COSHH and Why It Applies to Research Peptide Labs

COSHH is the UK regulatory framework requiring employers to control exposure to substances that can cause ill health, covering chemicals, fine powders, biological agents and any material capable of causing harm through inhalation, skin contact, ingestion or injection. Research peptides fall within this scope because they are typically supplied and handled as fine lyophilised powders or concentrated solutions — physical forms that can pose inhalation or dermal exposure risks during weighing, transfer and reconstitution, even where the underlying compound has a favourable general safety profile. The Health and Safety Executive (HSE) expects any UK laboratory handling such substances to have a written, substance-specific risk assessment in place before work begins, not a generic one covering the lab as a whole.

How to Complete a COSHH Risk Assessment for Research Peptides (Step-by-Step)

A COSHH risk assessment for research peptides UK laboratories can build around five core steps, mirroring the standard HSE framework:

1. Identify the hazard — review the peptide's Certificate of Analysis (COA) and any available safety data to understand its physical form, purity, and known hazard classification.

2. Decide who might be harmed and how — consider researchers weighing powder, reconstituting solutions, disposing of sharps, and anyone cleaning the work area.

3. Evaluate the risk and existing controls — assess exposure routes (inhalation of dust, skin contact, accidental needlestick) and whether current lab controls (fume hood, PPE, ventilation) are adequate.

4. Record the significant findings — document the assessment in writing, including control measures and who is responsible for implementing them.

5. Review and update the assessment — repeat whenever a new peptide, batch, or handling procedure is introduced, and at a fixed interval regardless.

COSHH Hazards Specific to Handling Research Peptides

Peptides raise a narrower set of practical hazards than many laboratory chemicals, but several recur across almost every research setting:

• Inhalation of fine powder when opening vials or weighing out lyophilised material

• Skin or eye contact during reconstitution with bacteriostatic water, particularly if a vial is opened forcefully or over-pressurised

• Aerosol formation from splashing or vigorous mixing rather than gentle swirling

• Sharps injuries from needles and syringes used to reconstitute or transfer solutions

• Incorrect disposal of vials, needles, and reconstitution waste into general laboratory waste streams

Control Measures and PPE for COSHH-Compliant Peptide Handling

Once hazards are identified, COSHH requires proportionate controls. For most research peptide handling, this means:

• Weighing and opening lyophilised powder inside a fume hood or ventilated enclosure where practical

• Nitrile gloves and safety eyewear as a minimum for reconstitution and transfer steps

• Gentle swirling rather than shaking to reconstitute, reducing aerosol and splash risk

• A designated sharps bin for needles and syringes, disposed of via a licensed clinical waste route

• Hand washing and surface decontamination after handling, even when gloves have been worn

Documentation, Certificates of Analysis and Record-Keeping

A COSHH assessment is only as good as the information behind it, which is why the Certificate of Analysis supplied with each peptide batch matters beyond confirming purity — it also underpins the hazard identification step of the assessment by confirming exactly which compound and batch is on site. Best practice is to keep the COA, the COSHH assessment, and any incident or near-miss records together in the same batch file, and to update the assessment whenever a new compound, supplier, or reconstitution method is introduced. Institutions with a laboratory quality system will typically want assessments reviewed annually as a minimum, even where no new peptides have been added.

Common COSHH Mistakes UK Research Labs Make

• Treating all research peptides as uniformly low-risk without reviewing the specific compound's form and handling requirements

• Relying on a generic 'chemical handling' assessment instead of one specific to peptide powders and reconstituted solutions

• Not updating the assessment when a new peptide or a new batch with different documentation arrives

• Missing a specific spill or exposure procedure for reconstituted peptide solutions

• No COSHH training record for new researchers before they handle peptides unsupervised

Note: All research peptides supplied by Daxer Labs are intended strictly for laboratory and in-vitro research use by qualified professionals. They are not for human or animal consumption, diagnostic, therapeutic, or any other use outside a controlled research setting, and nothing in this article should be treated as a substitute for a site-specific COSHH assessment carried out by a competent person.

Sourcing Research Peptides That Support COSHH Compliance

Daxer Labs ships every research peptide from our Swiss manufacturing facility with a full Certificate of Analysis, giving UK laboratories the batch-specific documentation a COSHH assessment depends on. For labs building their reconstitution and handling procedures, our Bacteriostatic Water is available on the Daxer Labs shop alongside our full peptide range, each supported by the same documentation standard.

Frequently Asked Questions

Do research peptides need a COSHH risk assessment?

Yes. Under UK law, any substance capable of causing harm through inhalation, skin contact or other exposure route — including lyophilised peptide powders and reconstituted solutions — must be covered by a written COSHH risk assessment before it is used in a laboratory.

Are research peptides classified as hazardous substances under COSHH?

Research peptides are generally handled as substances hazardous to health because of their physical form (fine powder, concentrated solution) rather than acute toxicity, so COSHH applies to the handling process even when the compound itself carries a favourable general safety profile.

What PPE is recommended when handling research peptides?

Most laboratories require nitrile gloves and safety eyewear as a minimum, with fume hood or ventilated enclosure use recommended when weighing or opening lyophilised powder.

How often should a COSHH risk assessment for research peptides be reviewed?

At least annually, and immediately whenever a new peptide, batch, supplier, or handling procedure is introduced to the laboratory.

Who is responsible for completing the COSHH assessment — the researcher or the supplier?

The employer or laboratory, not the supplier, is legally responsible for the COSHH risk assessment. Suppliers can support the process by providing accurate Certificates of Analysis and batch documentation.

Does Daxer Labs provide documentation to support a COSHH assessment?

Yes. Every Daxer Labs peptide ships with a Certificate of Analysis confirming compound identity and purity, which laboratories can use as part of the hazard identification step of their own COSHH assessment.